SER-155 cut bloodstream infections after allogeneic transplant in a phase 1b study
Allogeneic hematopoietic cell transplantation remains one of the most intensive curative treatments in hematologic oncology, and it also creates a narrow post-transplant window in which gut barrier injury, microbial disruption, and systemic infection can turn dangerous quickly. In that setting, the investigational oral live biotherapeutic SER-155 entered testing with a simple clinical aim: restore enough intestinal microbial stability and epithelial support to blunt the cascade that leads to bloodstream infection.
The phase 1b program used two cohorts, one open-label and one partially randomized, placebo-controlled. The later cohort is the one that carries the strongest comparative signal: 34 participants underwent transplant after treatment assignment, with 20 receiving SER-155 after microbiome conditioning with oral vancomycin and 14 receiving placebo. The study population was adult allogeneic hematopoietic cell transplant recipients, the group in which bloodstream infection and graft-versus-host disease remain major drivers of early morbidity and mortality.
Safety stayed close to placebo while engraftment was documented across all strains
Tolerance of the live biotherapeutic was reassuring. SER-155 showed a safety profile comparable to placebo, with no treatment-related serious adverse events and no infections caused by SER-155 species. The most common adverse events were diarrhea and nausea, symptoms that fit the expected gastrointestinal context of transplant care and did not separate the product from a major safety concern signal.
Deaths occurred in both cohorts, but none were attributed to SER-155. Four participants died in cohort 1 and four in cohort 2, including two in the SER-155 arm and two in the placebo arm. In a population as medically fragile as post-transplant recipients, those numbers matter because any new oral microbiome therapy has to prove it can be layered onto existing immunosuppression, antimicrobial exposure, conditioning regimens, and mucosal injury without adding another source of harm.
The pharmacokinetic readout was also straightforward. Engraftment was detected for all 16 SER-155 strains, and after the first treatment course the median number of strains detected was 11.5. In practical terms, the product colonized or persisted in a biologically detectable way rather than disappearing immediately after administration, which is exactly the kind of signal expected from a cultivated multi-strain live biotherapeutic intended to influence the post-transplant gut environment.
Bloodstream infection fell sharply, but the broader secondary package was mixed
The most consequential efficacy result came from the key secondary endpoint. Bloodstream infection occurred in 10.0% of SER-155 recipients versus 43% of placebo recipients, corresponding to an odds ratio of 0.15, a 95% confidence interval of 0.01–1.13, a P value of 0.0423, and a 77% relative risk reduction. In a transplant setting where bacteremia can rapidly escalate, that separation is clinically meaningful even before the program reaches a larger confirmatory phase.
One sentence captures the central clinical tension: the bloodstream infection signal was strong, but not every downstream infection-related endpoint moved in the same direction.
Other secondary efficacy outcomes did not reach statistical significance. These included gastrointestinal infection, acute graft-versus-host disease of grade 2 or higher, febrile neutropenia, and a composite endpoint combining bloodstream infection, gastrointestinal infection, or acute graft-versus-host disease. The pattern suggests that SER-155 may be influencing a narrower biologic pathway than a broad immune complication bundle, or that the study was too small to show consistent effects across several interlocking endpoints.
The pharmacodynamic marker also failed to fully align with the infection result. GI domination by Enterococcus and Enterobacteriaceae species was not achieved. That finding is important because those organisms are often tied to dysbiosis in transplant recipients and have been implicated in microbial domination patterns associated with infectious complications. A therapy can still reduce bacteremia without fully normalizing the entire gut ecology, but the disconnect leaves open questions about which microbial or barrier-related mechanisms actually drove the observed benefit.
Why a live biotherapeutic matters in transplant care
The biological rationale for this approach is compelling. Allogeneic transplant disrupts the intestinal ecosystem through conditioning chemotherapy, antibiotics, and prolonged hospitalization, while mucosal barrier injury opens the door for bacteria to translocate into the bloodstream. A cultivated, multi-strain oral product is designed to intervene on that pathway from the luminal side rather than by suppressing pathogens alone. In theory, restoring microbial competition, metabolic balance, and epithelial resilience could reduce the probability that gut organisms seed the blood during the highest-risk period.
SER-155 is unusual because it is not being tested as a conventional antimicrobial and not as a classic probiotic supplement. It is a live biotherapeutic product developed specifically for the transplant context, where the goal is not simply to populate the gut with harmless organisms but to alter a high-risk microbial state after allogeneic transplantation. The trial’s design, including microbiome conditioning with oral vancomycin before SER-155 in the randomized cohort, reflects the practical reality that any colonization attempt has to compete with a heavily disrupted and antibiotic-exposed intestinal environment.
What the phase 1b result can and cannot support
The study supports feasibility, tolerability, and biological activity. It also suggests a possible reduction in bloodstream infection, which is the most clinically persuasive signal in the dataset. But the trial was small, and several important endpoints remained negative or inconclusive. The confidence interval around the BSI estimate is wide, and the secondary outcome package did not show consistent benefit across infection and inflammatory complications.
For now, the cleanest interpretation is that SER-155 deserves further study as a transplant-supportive live biotherapeutic with a plausible mechanism and an early efficacy signal against bloodstream infection. The unresolved issues are just as important: whether the product can reproducibly alter the gut ecosystem beyond the measured strain engraftment, whether the BSI signal survives in a larger trial, and whether the absence of full GI domination by Enterococcus and Enterobacteriaceae signals a limitation of the current formulation or a mismatch between the biomarker and the true mechanism of benefit.
Those questions will determine whether this approach becomes a niche microbiome intervention or a more durable part of infection prevention after allogeneic hematopoietic cell transplantation.